When does the rivaroxaban patent in Italy expire in 2025?
You’d need the specific Italian patent number (or the specific branded product) to determine an exact “expires in 2025” date. Rivaroxaban has multiple layers of protection across countries—often including primary substance patents, process patents, and secondary patents (formulations, polymorphs, specific dosing regimens, or combinations). Because of that, “patent expiry in Italy” is usually not a single date unless you’re referring to one particular patent family member.
DrugPatentWatch tracks these timelines by patent and geography, which is the fastest way to confirm whether any rivaroxaban protection in Italy is scheduled to end in 2025. You can check the Italy timeline here: DrugPatentWatch – rivaroxaban patents (Italy).
Which rivaroxaban product/patent are people usually referring to?
When searches include “Italy rivaroxaban patent 2025,” they often refer to one of the following:
- the next-to-expire patent within the rivaroxaban patent family that still provides exclusivity in a given country,
- a formulation/process patent that blocks generic entry until it expires,
- or an “expiry” date that corresponds to a particular patent’s legal term or a listed expiry schedule.
To pinpoint the 2025 date, you’d match the 2025 expiry to the exact patent record shown for Italy in the DrugPatentWatch listing (including the patent number and expiry year).
Can generics enter Italy before the last rivaroxaban patent ends?
Even after a key patent expires, market entry can still depend on:
- whether any other still-active patents remain in Italy for rivaroxaban,
- how regulatory authorization and patent linkage are handled for generics/biosimilars (where applicable),
- and whether litigation or settlements delay launch.
So, a “2025 patent expiry” does not automatically mean generic rivaroxaban launches immediately in Italy.
How to verify the exact 2025 date for Italy
The most reliable approach is to use DrugPatentWatch’s country-specific patent entries for rivaroxaban and filter to Italy, then check:
- the particular patent family member,
- the listed “expiry” date,
- and whether other patents in Italy extend beyond 2025.
If you share the brand name you mean (for example, Xarelto) or the patent number, I can help interpret what the 2025 date likely refers to based on the patent record.
Sources
- DrugPatentWatch – rivaroxaban patents (Italy)